Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Editorial

Cellular metabolism therapy

Author: Salvatore Nesci

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Excerpt

We are delighted to announce the launch of Cellular Metabolism Therapy, a new section of the Journal of Translational Medicine. “From benchside to bedside to community” are the cornerstones of translational medicine to improve the prevention, diagnosis and therapies with the final goal to maintain and improve human health. Cellular Metabolism Therapy as a new section aims at promoting the translation of basic research emerging from biochemistry, molecular medicine, physiology and biotechnology into cell metabolism in order to be exploited in clinical applications. Studies considered for publication cover any aspect of translational metabolic research, including (but not limited to): genetic disorders and epigenetic diseases; metabolic derangements causing neurodegeneration; immunometabolism; stroke; cardiovascular diseases; tumours; stem cell bioenergetics; ageing; carbohydrate, lipid, and protein metabolism. …
Literature
1.
Zalckvar E, Schuldiner M. Beyond rare disorders: A new era for peroxisomal pathophysiology. Mol Cell. 2022;82:2228–35.CrossRef
2.
Hirano M, Emmanuele V, Quinzii CM. Emerging therapies for mitochondrial diseases. Essays Biochem. 2018;62:467–81.CrossRef
3.
Nesci S, Trombetti F, Pagliarani A, Ventrella V, Algieri C, Tioli G, et al. Molecular and supramolecular structure of the mitochondrial oxidative phosphorylation system: implications for pathology. Life. 2021;11:242.CrossRef
4.
Fernandez-Vizarra E, Zeviani M. Mitochondrial disorders of the OXPHOS system. FEBS Lett. 2021;595:1062–106.CrossRef
5.
Castro IG, Schuldiner M, Zalckvar E. Mind the organelle gap – peroxisome contact sites in disease. Trends Biochem Sci. 2018;43:199–210.CrossRef
6.
Garone C, Pietra A, Nesci S. From the structural and (Dys) function of ATP synthase to deficiency in age-related diseases. Life (Basel). 2022;12:401.
7.
Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19:609–33.CrossRef
8.
Fu W, Liu Y, Yin H. Mitochondrial dynamics: biogenesis, fission, fusion, and mitophagy in the regulation of stem cell behaviors. Stem Cells Int. 2019;2019:9757201.PubMedPubMedCentral
9.
Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38:633–43.CrossRef
10.
Ryan DG, Murphy MP, Frezza C, Prag HA, Chouchani ET, O’Neill LA, et al. Coupling Krebs cycle metabolites to signalling in immunity and cancer. Nat Metab. 2019;1:16–33.CrossRef
11.
Murphy MP, O’Neill LAJ. How should we talk about metabolism? Nat Immunol. 2020;21:713–5.CrossRef
12.
O’Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol Nature Publishing Group. 2016;16:553–65.CrossRef
13.
Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431–5.CrossRef
Metadata
Title
Cellular metabolism therapy
Author
Salvatore Nesci
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03514-4

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Increased expression of six-large extracellular vesicle-derived miRNAs signature for nonvalvular atrial fibrillation

Research

TGF-β1 induced deficiency of linc00261 promotes epithelial–mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3

Research

The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis

Correction

Correction: Cross validated serum small extracellular vesicle microRNAs for the detection of oropharyngeal squamous cell carcinoma

Commentary

Autoimmunity is a hallmark of post-COVID syndrome

Research

Identification of DNA methylation-regulated differentially expressed genes in RA by integrated analysis of DNA methylation and RNA-Seq data
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits